# Rituximab Vasculitis Maintenance Study

> **NCT01697267** · PHASE3 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 188 (actual)

## Conditions studied

- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Microscopic Polyangiitis
- Wegener Granulomatosis

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT01697267
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2018-11-22
- **Final completion:** 2019-11-21
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697267, "Rituximab Vasculitis Maintenance Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01697267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*